STOCK TITAN
  1. Home
  2. Sec-filings
  3. AQST
  4. [Form 4] Aquestive Therapeutics, Inc. Insider Trading Activity

Aquestive Therapeutics (AQST) CEO awarded 293,100 performance stock units tied to share price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. President and CEO Daniel Barber received a grant of 293,100 Performance Stock Units (PSUs) on March 7, 2025. Each PSU represents a contingent right to receive one share of common stock at no exercise price.

The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. The award’s “Performance Price” is based on specified 30-day average Nasdaq closing prices during two measurement periods within this three-year term. The filing notes it was submitted late due to an inadvertent administrative oversight.

Positive

  • None.

Negative

  • None.
Insider Barber Daniel
Role President and CEO
Type Security Shares Price Value
Grant/Award Performance Stock Units 293,100 $0.00 --
Holdings After Transaction: Performance Stock Units — 293,100 shares (Direct)
Footnotes (1)
  1. This Form 4 was filed late due to an inadvertent administrative oversight. Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).
PSU grant size 293,100 units Performance Stock Units granted on March 7, 2025
Underlying shares 293,100 shares Each PSU represents one share of common stock
Exercise price $0.00 per share Conversion or exercise price for PSUs
Vesting date March 7, 2028 Earned PSUs vest 100% on this date
PSUs outstanding after grant 293,100 units Total Performance Stock Units following this transaction
Performance Stock Units financial
"security_title": "Performance Stock Units""
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
Grant Date financial
"measure performance from March 7, 2025 (Grant Date) through March 7, 2028"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
Performance Price financial
""Performance Price" means (i) the 30-day average Nasdaq closing price"
30-day average Nasdaq closing price financial
"the 30-day average Nasdaq closing price ending on the last day of the period"
First Pricing Period financial
"ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period)"
Second Pricing Period financial
"during the period from the second through the third anniversary (Second Pricing Period)"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Barber Daniel
(Last)(First)(Middle)
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
(Street)
WARREN NEW JERSEY 07059
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/07/2025		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units(1)(2)03/07/2025A293,100 (2)03/07/2028Common Stock293,100$0293,100D
Explanation of Responses:
1. This Form 4 was filed late due to an inadvertent administrative oversight.
2. Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).
Remarks:
/s/ Lori Braender, as Attorney-In-Fact04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aquestive Therapeutics (AQST) report for Daniel Barber?

Aquestive Therapeutics reported that President and CEO Daniel Barber received a grant of 293,100 Performance Stock Units on March 7, 2025. These units are a form of equity compensation that may convert into common shares if performance conditions are met over a three-year period.

How many Performance Stock Units were granted to the AQST CEO?

Daniel Barber received 293,100 Performance Stock Units tied to Aquestive Therapeutics common stock. Each unit can convert into one share if defined performance goals are achieved during the measurement period, with all earned units vesting together at the end of the three-year term.

When do Daniel Barber’s AQST Performance Stock Units vest?

All earned Performance Stock Units for Daniel Barber vest 100% on March 7, 2028. Vesting depends on meeting performance conditions measured from March 7, 2025 through March 7, 2028, so the actual number of shares delivered will depend on future performance results.

What is the 'Performance Price' for the AQST Performance Stock Units?

The Performance Price is based on 30-day average Nasdaq closing prices over two periods within the three-year term. One average is taken ending just before the second anniversary, and the second is the highest 30-day average between the second and third anniversaries of the March 7, 2025 grant date.

Did Aquestive Therapeutics (AQST) note any issues with this Form 4 filing?

The company disclosed that this Form 4 was filed late due to an inadvertent administrative oversight. This comment relates to the timing of the regulatory filing and does not change the underlying grant terms for the Performance Stock Units awarded to the CEO.

What type of security underlies the AQST Performance Stock Units granted to the CEO?

Each Performance Stock Unit corresponds to one share of Aquestive Therapeutics common stock. If the specified performance conditions are satisfied over the three-year period, the earned PSUs convert into common shares, providing the CEO with direct equity exposure to the company.